Douglas Calder
Vermögen: 4 657 $ am 31.05.2026
Vermögen: 4 657 $ am 31.05.2026
Douglas W.
Calder is currently an Independent Director at Zevra Therapeutics, Inc. since 2023, a Director at BioFlorida, Inc. since 2019, a Director at Nextgennk since 2019, an Independent Director at Lunai Bioworks, Inc. since 2024, and a Member of the Society For Natural Immunity since 2018.
Former roles include Director-Investor Relations & Public Relations at Accentia Biopharmaceuticals, Inc. from 2012 to 2013, President & Director at Vycellix, Inc., VP-Strategic Planning & Capital Markets at BioVest International, Inc. from 2012 to 2013, Executive Vice President at Pulse Evolution Corp., President at VyGen-Bio, Inc., and Portfolio Manager at Dean Witter Reynolds, Inc. and Gruntal & Co. LLC.
Education includes undergraduate studies at Florida State University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LUNAI BIOWORKS, INC. 0.03% | 10.04.2026 | 1’512 ( 0.03% ) | 4 657 $ | 31.05.2026 |
| 06.04.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 25.04.2023 |
| LUNAI BIOWORKS INC. | Direktor/Vorstandsmitglied | 14.10.2024 |
Nextgennk | Direktor/Vorstandsmitglied | 01.06.2019 |
BioFlorida, Inc.
BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services Provides infrastructure to exchange information and ideas through industry specific programming, education, networking and legislative initiatives. | Direktor/Vorstandsmitglied | 01.01.2019 |
| Unternehmen | Position | Ende |
|---|---|---|
BioVest International, Inc.
BioVest International, Inc. Medical SpecialtiesHealth Technology Develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers | Investor Relations Kontakt | 16.07.2013 |
| ACCENTIA BIOPHARMACEUTICALS INC | Investor Relations Kontakt | 04.03.2013 |
Dean Witter Reynolds, Inc.
Dean Witter Reynolds, Inc. Investment ManagersFinance Investment management | Corporate Officer/Principal | - |
Gruntal & Co. LLC
Gruntal & Co. LLC General GovernmentGovernment Provides financial services | Corporate Officer/Principal | - |
VyGen-Bio, Inc.
VyGen-Bio, Inc. BiotechnologyHealth Technology Develops cell & gene therapies and treatments for cancer | Präsident | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 12 |
|---|---|
BioVest International, Inc.
BioVest International, Inc. Medical SpecialtiesHealth Technology Develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers | Health Technology |
Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceuticals | Health Technology |
Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets proprietary prodrugs | Health Technology |
Lunai Bioworks, Inc.
Lunai Bioworks, Inc. BiotechnologyHealth Technology Operates as preclinical stage biotechnology company developing technologies and therapies for HIV, HBV and cancer | Health Technology |
Pulse Evolution Corp.
Pulse Evolution Corp. Information Technology ServicesTechnology Services Produces photorealistic digital humans and provides digital production | Technology Services |
Dean Witter Reynolds, Inc.
Dean Witter Reynolds, Inc. Investment ManagersFinance Investment management | Finance |
Gruntal & Co. LLC
Gruntal & Co. LLC General GovernmentGovernment Provides financial services | Government |
Florida State University
Florida State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioFlorida, Inc.
BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services Provides infrastructure to exchange information and ideas through industry specific programming, education, networking and legislative initiatives. | Commercial Services |
Vycellix, Inc.
Vycellix, Inc. BiotechnologyHealth Technology Engages in the development of transformational platform technologies for cell & gene-based therapies | Health Technology |
Nextgennk | |
VyGen-Bio, Inc.
VyGen-Bio, Inc. BiotechnologyHealth Technology Develops cell & gene therapies and treatments for cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen